Fragile X targeted pharmacotherapy: lessons learned and future directions

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Fragile X syndrome (FXS) is a single-gene disorder with complex pathophysiology.
• Current FXS management relies on symptom-based treatments as no approved drugs exist.
• Numerous drug targets have been identified, yet translational success has been limited.

Purpose of the Study:

• To review the current understanding of FXS pathophysiology and phenotype.
• To analyze the rationale and outcomes of past clinical trials for FXS drug development.
• To discuss challenges and propose lessons for future FXS treatment strategies.

Main Methods:

• Literature review of FXS pathophysiology, phenotype, and clinical trial data.
• Analysis of drug mechanisms targeting neurotransmission (glutamatergic, GABAergic) and other pathways.
• Synthesis of challenges in clinical trial design, outcome measures, and target selection.

Main Results:

• Despite promising preclinical data, FXS drug development has largely failed in clinical trials.
• Many trials focused on neurotransmission, but diverse mechanisms were explored.
• Past trials faced challenges in design, outcome measures, and patient selection.

Conclusions:

• Translational drug development for FXS requires learning from past challenges.
• Improving clinical trial design, selecting appropriate outcome measures, and identifying suitable drug targets are crucial.
• Continued exploration of novel mechanistic approaches and enhanced trial execution is essential for future FXS therapies.